A concentration of 2.5 X 10(-5) M 2-mercaptoethanol (2-ME) added to the medium in lymphocyte blastogenesis assays increased both the uptake of [3H]thymidine in unstimulated lymphocyte cultures and the probability of detecting antigen-sensitized cattle. The use of 2-ME did not cause lymphocytes from unsensitized cattle to react positively in blastogenesis assays. A crude brucella lysate prepared from Brucella abortus strain 19 was compared with a well-characterized brucella protein allergen prepared from B melitensis and was found to be equally suitable for use in blastogenesis assays. Cell-mediated immunity was produced most effectively in 4-month-old calves by tetanus toxoid, then by Mycobacterium bovis, and least effectively by B abortus.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Differences in the intrahepatic expression of immune checkpoint molecules on T cells and natural killer cells in chronic HBV patients.
Front Immunol
January 2025
Univ. Grenoble Alpes, Inserm U 1209, CNRS UMR 5309, Institute for Advanced Biosciences, Grenoble, France.
Background: Patients with chronic hepatitis B virus (HBV) infection are characterized by impaired immune response that fails to eliminate HBV. Immune checkpoint molecules (ICMs) control the amplitude of the activation and function of immune cells, which makes them the key regulators of immune response.
Methods: We performed a multiparametric flow cytometry analysis of ICMs and determined their expression on intrahepatic lymphocyte subsets in untreated and treated patients with HBV in comparison with non-pathological liver tissue.
The neutrophil-lymphocyte ratio as a risk factor for all-cause mortality among individuals with resolved HBV infection: evidence from the NHANES 1999-2018.
Front Public Health
January 2025
Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
Background: Inflammation is a critical component in the process of resolved hepatitis B virus (HBV) infection. The neutrophil-to-lymphocyte ratio (NLR) serves as a sensitive indicator of systemic inflammation and immune activation. Our study aimed to investigate the correlation between elevated NLR levels and the risk of all-cause mortality in patients with resolved HBV infection.
View Article and Find Full Text PDFBryostatin-1 enhances the proliferation and functionality of exhausted CD8+ T cells by upregulating MAP Kinase 11.
Front Immunol
January 2025
Department of Immunology, Erasmus University Medical Center, Rotterdam, Netherlands.
Introduction: Bryostatin-1, a potent agonist of the protein kinase C, has been studied for HIV and cancer therapies. In HIV research, it has shown anti-HIV effects during acute infection and reactivation of latent HIV in chronic infection. As effective CD8+ T cell responses are essential for eliminating reactivated virus and achieving a cure, it is important to investigate how bryostatin-1 affects HIV-specific CD8+ T cells.
View Article and Find Full Text PDFNLRX1 limits inflammatory neurodegeneration in the anterior visual pathway.
J Neuroinflammation
January 2025
Department of Neurology, Division of Neuroimmunology, School of Medicine, Johns Hopkins University, Baltimore, MD, 21287, USA.
Chronic innate immune activation in the central nervous system (CNS) significantly contributes to neurodegeneration in progressive multiple sclerosis (MS). Using multiple experimental autoimmune encephalomyelitis (EAE) models, we discovered that NLRX1 protects neurons in the anterior visual pathway from inflammatory neurodegeneration. We quantified retinal ganglion cell (RGC) density and optic nerve axonal degeneration, gliosis, and T-cell infiltration in Nlrx1 and wild-type (WT) EAE mice and found increased RGC loss and axonal injury in Nlrx1 mice compared to WT mice in both active immunization EAE and spontaneous opticospinal encephalomyelitis (OSE) models.
View Article and Find Full Text PDFTransient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial.
J Immunother Cancer
January 2025
Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland
Article Synopsis
- TILT-123, an oncolytic virus engineered to enhance T-cell responses, was tested in the TUNIMO trial on 20 patients with advanced solid tumors to evaluate its safety, efficacy, and immunological effects.
- The study found that a greater decrease in blood lymphocyte count after treatment was associated with better tumor response and longer overall survival, which was corroborated by an external dataset of 96 patients.
- Analysis of tumor biopsies revealed an increase in immune cells, specifically CD8+ T cells, CD4+ T cells, and NK cells, suggesting that TILT-123 activates the immune response effectively in patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!